Access cutting-edge common variable immunodeficiency treatment through this phase 4 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Birmingham location
Preparing your pre-screening questions…
Access common variable immunodeficiency specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related common variable immunodeficiency treatment provided free
Check if you qualify for this common variable immunodeficiency clinical trial in Birmingham, AL
No-Cost Study Care
Local to Birmingham
Convenient for AL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published study to guide immunologists regarding the use of spirometry in titrating IG therapy to assist in the management of immunodeficiency patients with regards to gammaglobulin replacement therapy. The investigators propose to study the use of spirometry to identify patients that could potentially benefit from an increase in IGRT. The investigators will identify 22 common variable immune deficiency (CVID) study subjects on stable IGRT replacement therapy equivalent to 0.40 to 0.60 gm/kg per 4 weeks who have evidence of mild to moderate obstruction as assessed by an FEF25-75% between 50% and 80% of predicted. Patients who are on Hizentra will be preferentially recruited. Of these 22, 11 will be identified at random and treated for 6 months at their current dose (control population). The remaining 11 study subjects (treatment group) will have their level of IGRT increased by the equivalent of 0.05 gm/kg in dose per 4 weeks, adjusted for bioavailability as per manufacturer's instructions. On average, rounded up to the nearest gram, this will typically increase their dose of Hizentra by 2 gm per week.
Sponsor: University of Alabama at Birmingham
Yes, this clinical trial (NCT05193552) has an active research site in Birmingham, AL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for common variable immunodeficiency treatment options in Birmingham, AL, this clinical trial (NCT05193552) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced common variable immunodeficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all common variable immunodeficiency clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Birmingham — not just this study.
Browse Multiple Myeloma Trials in Birmingham →